Medindia LOGIN REGISTER
Medindia
Advertisement

Pharmasset Selected to Join the NASDAQ Biotechnology Index

Tuesday, May 13, 2008 General News
Advertisement
PRINCETON, N.J., May 12 Pharmasset, Inc.(Nasdaq: VRUS), a clinical stage pharmaceutical company committed todiscovering, developing and commercializing novel drugs to treat viralinfections, is pleased to announce that it has been selected to join theNASDAQ Biotechnology Index effective with the market open on May 19, 2008.
Advertisement

The NASDAQ Biotechnology Index is the basis for the iShares NASDAQBiotechnology Index(sm) Fund (AMEX: IBB), which seeks investment results thatcorrespond generally to the price and yield performance, before fees andexpenses, of the NASDAQ Biotechnology Index. In addition, options based on theNASDAQ Biotechnology Index and the iShares NASDAQ Biotechnology Index Fundtrade on various exchanges. For more information about the NASDAQBiotechnology Index, including eligibility criteria, visithttp://www.nasdaq.com.
Advertisement

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed todiscovering, developing and commercializing novel drugs to treat viralinfections. Pharmasset's primary focus is on the development of oraltherapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus(HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine,for the treatment of chronic HBV infection, is enrolling Phase 3 clinicaltrials for registration in North, Central and South America and Europe.Clevudine is already approved for HBV in South Korea and marketed by BukwangPharmaceuticals in South Korea under the brand name Levovir. R7128, an oraltreatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial incombination with Pegasys(R) plus Copegus(R) through a strategic collaborationwith Roche. Racivir, which is being developed for the treatment of HIV incombination with other approved HIV drugs, has completed a Phase 2 clinicaltrial.

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities LitigationReform Act of 1995: Statements in this press release regarding our businessthat are not historical facts are "forward-looking statements" that involverisks and uncertainties, including without limitation the risk that Pharmassetdoes not become a part of the Nasdaq Biotechnology Index, the risk thatadverse events could cause the cessation or delay of any of the ongoing orplanned clinical trials and/or our development of our product candidates, therisk that we cannot enroll enough patients for the Phase 3 registrationclinical trial for clevudine, the risk that our collaboration with Roche willnot continue or will not be successful and the risk that any one or more ofour product candidates will not be successfully developed and commercialized.For a discussion of these risks and uncertainties, any of which could causeour actual results to differ from those contained in the forward-lookingstatements, see the section of our Annual Report on Form 10-K for the fiscalyear ended September 30, 2007 filed with the Securities and ExchangeCommission entitled "Risk Factors" and discussions of potential risks anduncertainties in our subsequent filings with the Securities and ExchangeCommission.Pegasys(R) and Copegus(R) are registered trademarks of Roche. Contact Alan Roemer, Vice President Investor Relations & Corporate Communications [email protected] Office: (609) 613-4125

SOURCE Pharmasset, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close